Alimera Sciences Added To Russell 2000®, 3000® And Global Indexes

ATLANTA, July 1, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the Russell 2000® Index, Russell 3000® Index and Russell Global Index as part of the annual reconstitution by Russell Investments of its comprehensive set of U.S. and global equity indexes on June 28, 2013.

“We are pleased to be added to the Russell Global Indexes, and believe our inclusion will generate further interest among those in the investment community who may be less familiar with Alimera,” said Dan Myers, Alimera’s president and chief executive officer.

Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 2000 and 3000 remains in place for one year. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. In the institutional marketplace, an industry-leading $3.9 trillion in assets currently are benchmarked to them. Based on Russell’s procedures, Alimera will hold its membership until Russell reconstitutes its indexes in June 2014.

About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN^®, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

SOURCE Alimera Sciences, Inc.